C

Corline Biomedical AB
STO:CLBIO

Watchlist Manager
Corline Biomedical AB
STO:CLBIO
Watchlist
Price: 17 SEK -1.16% Market Closed
Market Cap: 416.3m SEK
Section:
 

Relative Value

The Relative Value of one CLBIO stock under the Base Case scenario is 23.53 SEK. Compared to the current market price of 17 SEK, Corline Biomedical AB is Undervalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLBIO Relative Value
Base Case
23.53 SEK
Undervaluation 28%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

55.1
P/S
P/S
Price to Sales
55.1
vs History
14
vs Industry
7
Median 3Y
12.6
Median 5Y
23.6
Industry
2.6
Forward
14.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-30.7
Industry
21.6
Forward
30.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
10
Median 3Y
-27.2
Median 5Y
-38.1
Industry
16.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-19.6
Median 5Y
-17.8
Industry
22.5
More Details
5.4
P/B
P/B
Price to Book Value
5.4
vs History
6
vs Industry
27
Median 3Y
2.9
Median 5Y
3
Industry
2.3
More Details
54.3
EV/S
EV/S
Enterprise Value to Sales
54.3
vs History
12
vs Industry
8
Median 3Y
11.9
Median 5Y
21.8
Industry
2.9
Forward
14.2
More Details
65.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
65.8
vs History
4
vs Industry
13
Median 3Y
10.6
Median 5Y
15.9
Industry
5.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-17.2
Median 5Y
-31.8
Industry
13
Forward
99.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-31.7
Industry
16.6
Forward
99.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
11
Median 3Y
-26.3
Median 5Y
-32.3
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-18.4
Median 5Y
-16.7
Industry
19.1
More Details
5.4
EV/IC
EV/IC
Enterprise Value to IC
5.4
vs History
9
vs Industry
25
Median 3Y
3.1
Median 5Y
3.6
Industry
1.9
More Details

Multiples Across Competitors

CLBIO Competitors Multiples
Corline Biomedical AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Corline Biomedical AB
STO:CLBIO
416.3m SEK 55.1 -17.5 -29.9 -29.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.8 54.3 36.5 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
514.8B USD 5.6 20.5 16.7 21.7
CH
Roche Holding AG
SIX:ROG
255.4B CHF 4.1 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
211.2B GBP 4.9 30.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
204.2B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
247.6B USD 3.8 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
149.9B USD 2.4 15.2 7.7 10.5
P/E Multiple
Earnings Growth PEG
SE
C
Corline Biomedical AB
STO:CLBIO
Average P/E: 23.9
Negative Multiple: -17.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
C
Corline Biomedical AB
STO:CLBIO
Average EV/EBITDA: 438.9
Negative Multiple: -29.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
C
Corline Biomedical AB
STO:CLBIO
Average EV/EBIT: 1 881.3
Negative Multiple: -29.7 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3

See Also

Summary
CLBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLBIO stock valuation using valuation multiples.
Wall Street Estimates
CLBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.